We are developing a platform to transform dementia and related neurodegenerative diseases. Our lead therapeutic, CT-526, has reversed Alzheimer's disease in multiple animal models by targeting a previously "undruggable"; target called CDK5. We are continuing to develop it in collaboration with scientists at NIH and Johns Hopkins. Our companion diagnostic can "biopsy" brain tissue with a blood test and stratify patients for therapy as well as monitor target engagement in clinical trials. This noninvasive technique will enhance the entire field of neurological therapeutics. We are currently de-risking our platform for early partnership with Pharma.
Cogentis Therapeutics is presenting as part of the NIH Innovation Zone.